These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8506414)

  • 1. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi.
    Elder DE; Clark WH; Elenitsas R; Guerry D; Halpern AC
    Semin Diagn Pathol; 1993 Feb; 10(1):18-35. PubMed ID: 8506414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
    Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
    Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Focal melanocytic atypia in dysplastic nevus cell nevi. Results of a serial section study].
    Sigg C; Pelloni F; Schnyder UW
    Hautarzt; 1989 Nov; 40(11):701-7. PubMed ID: 2606669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysplastic melanocytic nevi and prognostically indeterminate nevomelanomatoid proliferations.
    Kim JC; Murphy GF
    Clin Lab Med; 2000 Dec; 20(4):691-712. PubMed ID: 11221510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of melanoma precursor lesions.
    Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
    Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysplastic nevi and other risk markers for melanoma.
    Seykora J; Elder D
    Semin Oncol; 1996 Dec; 23(6):682-7. PubMed ID: 8970587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Borderline and atypical melanocytic lesions.
    Brodell RT; Santa Cruz DJ
    Semin Diagn Pathol; 1985 Feb; 2(1):63-86. PubMed ID: 3916688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
    Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
    Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology.
    Rhodes AR; Mihm MC; Weinstock MA
    Mod Pathol; 1989 Jul; 2(4):306-19. PubMed ID: 2762287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
    Clark WH; Hood AF; Tucker MA; Jampel RM
    Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma.
    Banky JP; Kelly JW; English DR; Yeatman JM; Dowling JP
    Arch Dermatol; 2005 Aug; 141(8):998-1006. PubMed ID: 16103329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness.
    Roesch A; Burgdorf W; Stolz W; Landthaler M; Vogt T
    Eur J Dermatol; 2006; 16(5):479-93. PubMed ID: 17101467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysplastic nevus--risk factor or disguise for melanoma.
    Dediol I; Bulat V; Zivković MV; Marković BM; Situm M
    Coll Antropol; 2011 Sep; 35 Suppl 2():311-3. PubMed ID: 22220461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problems with lesions related to the development of malignant melanoma: common nevi, dysplastic nevi, malignant melanoma in situ, and radial growth phase malignant melanoma.
    Clark WH; Tucker MA
    Hum Pathol; 1998 Jan; 29(1):8-14. PubMed ID: 9445128
    [No Abstract]   [Full Text] [Related]  

  • 18. Dysplastic nevus (atypical nevus).
    Rezze GG; Leon A; Duprat J
    An Bras Dermatol; 2010; 85(6):863-71. PubMed ID: 21308311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma risk in individuals with clinically atypical nevi.
    Kang S; Barnhill RL; Mihm MC; Fitzpatrick TB; Sober AJ
    Arch Dermatol; 1994 Aug; 130(8):999-1001. PubMed ID: 8053717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study addressed to understanding what predicts severe histological dysplasia/early melanoma in excised atypical melanocytic lesions.
    Strauss RM; Elliott F; Affleck P; Boon AP; Newton-Bishop JA
    Br J Dermatol; 2007 Oct; 157(4):758-64. PubMed ID: 17714559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.